SCEMBLIX is a targeted, oral therapy that works differently—
SCEMBLIX is a tyrosine kinase inhibitor (TKI) that targets the abnormal protein that causes Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) differently. It is the only TKI that is thought to bind to a different site (myristoyl pocket) within the abnormal protein that causes Ph+ CML-CP.
Ask your doctor if SCEMBLIX may be a good fit for you.
SCEMBLIX results
See how SCEMBLIX compared to commonly used TKIs.
What is Ph+ CML-CP?
Learn about the disease and what to expect with treatment.
Hear from patients
Hear from others who have CML IRL.
Interested in saving on SCEMBLIX?
Learn about resources for eligible patients who have been prescribed SCEMBLIX.
Considering SCEMBLIX?
Sign up for information about the medication and the disease.